Mercator is developing local and targeted micro-infusion solutions for diseases of the Peripheral Vasculature
DEXTERITY comprises two trials, one in acute DVT and one in subacute and chronic DVT, to reduce the chronic negative outcomes (post-thrombotic syndrome) associated with local inflammation.
The DEXTERITY-AFP and -SCI clinical trials will provide the critical evidence that local anti-inflammatory steroid delivery can improve outcomes in DVT treatment in the pelvis and thigh – the two anatomical regions hindered by poor chronic outcomes.
The DEXTERITY clinical trials have FDA IND, UK MHRA and Irish HPRA approvals.
Latest From Our Newsroom
Mercator Announces Enrollment of First Patient in DEXTERITY-AFP Clinical Trial Treating Inflammation in Deep Vein Thrombosis
EMERYVILLE, Calif., November 3, 2021 - Mercator...
Bay Area Investor & Partnering Meetings –...
Boston Scientific Announces Agreement to Acquire...